Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...
In a report released today, Vijay Rakesh from Mizuho Securities maintained a Hold rating on Mobileye Global, Inc. Class A (MBLY – Research ...
Japan's Rakuten Group has decided not to seek a listing for Rakuten Securities on the Tokyo Stock Exchange, it said on ...
an unusual move after serving as president of Mizuho Securities Co., a group company. Sakai pushed a corporate downsizing agenda, which included cutting staff and integrating or closing bank ...
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
Mizuho Securities raised its recommendation on Vornado Realty Trust (NYSE:VNO) and Cousins Properties (NYSE:CUZ), and downgraded Kilroy Realty (NYSE:KRC), considering their geographic exposure and ...
MIDLAND, Texas, Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten ...
Mizuho Financial Group, Inc. operates as a holding company which engages in the provision of financial services such as banking, trust banking, securities, and others. It operates through the ...
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback